Hu14.18 is in the same class as Y-mAbs Therapeutics’ Danyelza (naxitamab), a GD2-targeting antibody that was approved as a second-line treatment for relapsed/refractory high-risk neuroblastoma ...
The survival rate for children with a rare but deadly cancer could one day be improved by adding an existing drug—which is ...
Dr David King, children’s doctor at Sheffield Children's NHS Foundation Trust and Children with Cancer UK researcher, said: “Children with neuroblastoma and MYCN currently receive some of the most ...
New potential treatment The study suggests that inhibiting METTL3 could be a new treatment strategy for high-risk neuroblastoma, especially for cases that are resistant to current therapies.
Hearing that your child has neuroblastoma can be frightening and overwhelming. It can be daunting to think about the treatments your child may need and how the experience will affect your child, your ...
Despite extensive treatment, Will’s neuroblastoma — an aggressive tumour affecting the peripheral nervous system — had relapsed. His father, Pat, was told they were out of options and needed ...
A drug used to manage copper levels could improve the odds for children battling neuroblastoma, new research in animal models ...
Canberra: A new study by researchers from The University of New South Wales (UNSW) in Australia suggests that health of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback